# Denali Therapeutics Inc.: Form 8-K, filed Apr 3, 2026

- Company: [Denali Therapeutics Inc.](/companies/dnli.md) (CIK 1714899)
- Form: 8-K
- Filed: 2026-04-03
- Accepted by EDGAR: Apr 3, 2026, 14:43 ET
- Period: 2026-04-03
- Accession: 0001714899-26-000042
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1714899/000171489926000042/dnli-20260403.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1714899/000171489926000042/

## Items reported

- Item 1.02: Termination of a material agreement
- Item 9.01: Financial statements and exhibits

## Sections

Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. https://www.sec.gov/Archives/edgar/data/1714899/000171489926000042/dnli-20260403.htm

Filed Apr 3, 2026.
Source: SEC EDGAR, the filing index for accession 0001714899-26-000042. Last ingested by Listed: Nov 3, 2026, 19:01 ET. No prices; not investment advice.
